These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11222463)

  • 1. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure.
    Bozkurt B; Torre-Amione G; Warren MS; Whitmore J; Soran OZ; Feldman AM; Mann DL
    Circulation; 2001 Feb; 103(8):1044-7. PubMed ID: 11222463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study.
    Padfield GJ; Din JN; Koushiappi E; Mills NL; Robinson SD; Cruden Nle M; Lucking AJ; Chia S; Harding SA; Newby DE
    Heart; 2013 Sep; 99(18):1330-5. PubMed ID: 23574969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence.
    Irwin MR; Olmstead R; Valladares EM; Breen EC; Ehlers CL
    Biol Psychiatry; 2009 Jul; 66(2):191-5. PubMed ID: 19185287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of radiation-induced healing delay by etanercept treatment in rat arteries.
    Sugiyama K; Yamaguchi M; Kuroda J; Takanashi M; Ishikawa Y; Fujii H; Ishii T; Esumi H
    Cancer Sci; 2009 Aug; 100(8):1550-5. PubMed ID: 19486011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
    Mann DL; McMurray JJ; Packer M; Swedberg K; Borer JS; Colucci WS; Djian J; Drexler H; Feldman A; Kober L; Krum H; Liu P; Nieminen M; Tavazzi L; van Veldhuisen DJ; Waldenstrom A; Warren M; Westheim A; Zannad F; Fleming T
    Circulation; 2004 Apr; 109(13):1594-602. PubMed ID: 15023878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.
    Chung ES; Packer M; Lo KH; Fasanmade AA; Willerson JT;
    Circulation; 2003 Jul; 107(25):3133-40. PubMed ID: 12796126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
    Anker SD; Coats AJ
    Int J Cardiol; 2002 Dec; 86(2-3):123-30. PubMed ID: 12419548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
    Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
    J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.
    Bozkurt B; Kribbs SB; Clubb FJ; Michael LH; Didenko VV; Hornsby PJ; Seta Y; Oral H; Spinale FG; Mann DL
    Circulation; 1998 Apr; 97(14):1382-91. PubMed ID: 9577950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
    Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
    N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending the 'host response' paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities.
    Buckel M; Maclean P; Knight JC; Lawler PR; Proudfoot AG
    Crit Care; 2023 Nov; 27(1):460. PubMed ID: 38012789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation and immunopharmacology in heart failure.
    Markousis-Mavrogenis G; Baumhove L; Al-Mubarak AA; Aboumsallem JP; Bomer N; Voors AA; van der Meer P
    Nat Rev Cardiol; 2024 Feb; 21(2):119-149. PubMed ID: 37709934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation as a therapeutic target in heart failure with preserved ejection fraction.
    Peh ZH; Dihoum A; Hutton D; Arthur JSC; Rena G; Khan F; Lang CC; Mordi IR
    Front Cardiovasc Med; 2023; 10():1125687. PubMed ID: 37456816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic cell death in disease-Current understanding of the NCCD 2023.
    Vitale I; Pietrocola F; Guilbaud E; Aaronson SA; Abrams JM; Adam D; Agostini M; Agostinis P; Alnemri ES; Altucci L; Amelio I; Andrews DW; Aqeilan RI; Arama E; Baehrecke EH; Balachandran S; Bano D; Barlev NA; Bartek J; Bazan NG; Becker C; Bernassola F; Bertrand MJM; Bianchi ME; Blagosklonny MV; Blander JM; Blandino G; Blomgren K; Borner C; Bortner CD; Bove P; Boya P; Brenner C; Broz P; Brunner T; Damgaard RB; Calin GA; Campanella M; Candi E; Carbone M; Carmona-Gutierrez D; Cecconi F; Chan FK; Chen GQ; Chen Q; Chen YH; Cheng EH; Chipuk JE; Cidlowski JA; Ciechanover A; Ciliberto G; Conrad M; Cubillos-Ruiz JR; Czabotar PE; D'Angiolella V; Daugaard M; Dawson TM; Dawson VL; De Maria R; De Strooper B; Debatin KM; Deberardinis RJ; Degterev A; Del Sal G; Deshmukh M; Di Virgilio F; Diederich M; Dixon SJ; Dynlacht BD; El-Deiry WS; Elrod JW; Engeland K; Fimia GM; Galassi C; Ganini C; Garcia-Saez AJ; Garg AD; Garrido C; Gavathiotis E; Gerlic M; Ghosh S; Green DR; Greene LA; Gronemeyer H; Häcker G; Hajnóczky G; Hardwick JM; Haupt Y; He S; Heery DM; Hengartner MO; Hetz C; Hildeman DA; Ichijo H; Inoue S; Jäättelä M; Janic A; Joseph B; Jost PJ; Kanneganti TD; Karin M; Kashkar H; Kaufmann T; Kelly GL; Kepp O; Kimchi A; Kitsis RN; Klionsky DJ; Kluck R; Krysko DV; Kulms D; Kumar S; Lavandero S; Lavrik IN; Lemasters JJ; Liccardi G; Linkermann A; Lipton SA; Lockshin RA; López-Otín C; Luedde T; MacFarlane M; Madeo F; Malorni W; Manic G; Mantovani R; Marchi S; Marine JC; Martin SJ; Martinou JC; Mastroberardino PG; Medema JP; Mehlen P; Meier P; Melino G; Melino S; Miao EA; Moll UM; Muñoz-Pinedo C; Murphy DJ; Niklison-Chirou MV; Novelli F; Núñez G; Oberst A; Ofengeim D; Opferman JT; Oren M; Pagano M; Panaretakis T; Pasparakis M; Penninger JM; Pentimalli F; Pereira DM; Pervaiz S; Peter ME; Pinton P; Porta G; Prehn JHM; Puthalakath H; Rabinovich GA; Rajalingam K; Ravichandran KS; Rehm M; Ricci JE; Rizzuto R; Robinson N; Rodrigues CMP; Rotblat B; Rothlin CV; Rubinsztein DC; Rudel T; Rufini A; Ryan KM; Sarosiek KA; Sawa A; Sayan E; Schroder K; Scorrano L; Sesti F; Shao F; Shi Y; Sica GS; Silke J; Simon HU; Sistigu A; Stephanou A; Stockwell BR; Strapazzon F; Strasser A; Sun L; Sun E; Sun Q; Szabadkai G; Tait SWG; Tang D; Tavernarakis N; Troy CM; Turk B; Urbano N; Vandenabeele P; Vanden Berghe T; Vander Heiden MG; Vanderluit JL; Verkhratsky A; Villunger A; von Karstedt S; Voss AK; Vousden KH; Vucic D; Vuri D; Wagner EF; Walczak H; Wallach D; Wang R; Wang Y; Weber A; Wood W; Yamazaki T; Yang HT; Zakeri Z; Zawacka-Pankau JE; Zhang L; Zhang H; Zhivotovsky B; Zhou W; Piacentini M; Kroemer G; Galluzzi L
    Cell Death Differ; 2023 May; 30(5):1097-1154. PubMed ID: 37100955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut-Heart Axis.
    Matsiras D; Bezati S; Ventoulis I; Verras C; Parissis J; Polyzogopoulou E
    J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.
    Jiang Y; Chen Y; Yu Q; Shi Y
    BioDrugs; 2023 Jan; 37(1):35-55. PubMed ID: 36592323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Bone Morphogenetic Protein Receptor Type 2 (
    Devendran A; Kar S; Bailey R; Trivieri MG
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP3 inflammasome: The rising star in cardiovascular diseases.
    Zheng Y; Xu L; Dong N; Li F
    Front Cardiovasc Med; 2022; 9():927061. PubMed ID: 36204568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?
    Scridon A; Balan AI
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of interleukin 1, interleukin 27, and TNF α genes in patients with ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy: A case-control study.
    Iravani Saadi M; Salami J; Abdi H; Kheradmand N; Nabi Bdolyousefi E; Torkamani M; Karimi Z; Agah S; Rahimian Z; Manafi A
    Health Sci Rep; 2022 Jul; 5(4):e701. PubMed ID: 35782303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.